Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pops: merger will "transform" Alkermes-EDT into "fully integrated company"

This article was originally published in Scrip

Executive Summary

The merger of Alkermes with Elan Drug Technologies (EDT) – subject to a shareholder vote in September 2011 - will result in the perception of Alkermes as a drug delivery company to change completely, Alkermes' CEO Richard Pops told Scrip. "The transaction will have the effect of significantly accelerating the business plan we have been looking at for the past few years," he explained. "We have been using our drug delivery partnerships as a stepping stone on the way to becoming a fully integrated company with an innovative pipeline of products." In addition, combining the two companies will be "financially transformative… When we put these two together, there will be very few comparable companies".

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel